Understanding how calcium signaling affects T cells in autoimmune conditions
Mechanism underlying regulation of Ca2+ signaling in local effector T cells
This study is looking at how certain channels in T cells help control calcium signals that activate your immune system, especially in people with autoimmune conditions like rheumatoid arthritis, to find better treatments that can reduce harmful inflammation without weakening your overall immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10788421 on NIH RePORTER |
What this research studies
This research investigates the role of CRAC channels in T cells, which are crucial for calcium signaling that activates immune responses. The focus is on local effector T cells that migrate to inflamed tissues during autoimmune conditions like rheumatoid arthritis. By exploring how these channels are regulated specifically in these T cells, the research aims to develop targeted therapies that can suppress harmful cytokine production without broadly suppressing the immune system. This approach could lead to more effective treatments for autoimmune diseases while minimizing side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune conditions, particularly rheumatoid arthritis.
Not a fit: Patients with non-autoimmune conditions or those not experiencing significant T cell involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that selectively reduce inflammation in autoimmune diseases, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting specific immune pathways, indicating potential for success with this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Gwack, Yousang — University of California Los Angeles
- Study coordinator: Gwack, Yousang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.